Odegard Valerie 4

What Happened Valerie Odegard, a director of Odyssey Therapeutics (ODTX), received a derivative award on 2026-05-07 covering 27,393 shares. The reported price is $0.00 (no cash paid at grant); the award is described as an option that will vest in full on May 7, 2027, contingent on continued service. This was a grant/award (not an open-market purchase or sale) so there was no immediate cash proceeds or share sale.

Key Details

• Transaction date: 2026-05-07; Filing date: 2026-05-11 (filed within the required two business days).
• Transaction type/code: Award/Grant (A); reported price per share: $0.00; quantity: 27,393 derivative shares.
• Vesting: Footnote F1 — “Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.”
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No 10b5-1, tax-withholding, or sale noted in the excerpt.

Context This was a company compensation award (a derivative grant that vests in one year), not an exercise or market trade. Such awards are common for directors and do not by themselves signal a buy/sell decision by the insider—value to the insider will depend on Odyssey’s future share price and any exercise/vesting mechanics.